Central Nervous System -Specific Protein (S100β)

Kit Name	Central Nervous System Specific Protein(S100β) Detection Kit
Method	Fluorescence dry quantitative immunoassay
Assay Measuring Range	0.010 ng/mL ~ 50.000 ng/mL
Incubation Time	5 min
Sample Type	Human serum, Plasma (EDTA)
Reference Range	≤ 0.105 ng/mL
Storage and Stability	18 months at 2°C–8°C.

Order Information

Catalog No.	Product	Test/Kit
FFS1B500C	Central Nervous System Specific Protein(S100β) Detection Kit	25

Corresponding platform

Learn about the details of the platform corresponding to this reagent

Jet-iStar Platform – FIA for Every Healthcare Setting

Introduction

S100β, a central nervous system-specific protein, is a low molecular weight EF-hand calcium-binding protein with diverse biological activities. It serves as a biomarker reflecting pathophysiological processes including CNS injury, inflammation, and degenerative changes.

Clinical Applications

Acute Cerebral Infarction (CIS)

Traumatic Brain Injury (TBI)

Neonatal Hypoxic-Ischemic Encephalopathy (HIE)

Subarachnoid Hemorrhage (SAH)

Neurological Monitoring Post-Cardiopulmonary Resuscitation

Acute Cerebral Infarction (CIS)

Early Diagnosis: Levels significantly elevate ~10 hours post-stroke.

Severity Assessment: Peaks at ~72 hours; correlates with infarct volume.

Treatment Monitoring: Declining levels indicate therapeutic efficacy.

Prognosis: Serum concentrations predict clinical/functional outcomes.

Traumatic Brain Injury (TBI)

Early Diagnosis: Elevates within 6 hours, indicating secondary injury.

Severity Correlation: Levels increase with injury severity.

Prognosis: Higher concentrations predict poorer outcomes.

Neonatal Hypoxic-Ischemic Encephalopathy (HIE)

Early Diagnosis: Early elevation inversely correlates with Apgar scores.

Severity Grading: Concentrations rise with HIE severity (mild→moderate→severe).

Prognosis: Predicts long-term sequelae/mortality, especially in moderate-severe cases.

Subarachnoid Hemorrhage (SAH)

Severity Assessment: Strong positive correlation with initial hemorrhage severity.

Prognosis: Higher levels indicate poorer outcomes; associates with post-SAH cerebral infarction.

Neurological Monitoring Post-Cardiopulmonary Resuscitation

Recommended in 2019 Expert Consensus on Early Neurological Prognosis Assessment for continuous monitoring:

Brain injury causes 68% of post-resuscitation deaths and long-term disability.

Serial S100β testing enables neuroprotective intervention guidance.